Zanidatamab
Based on 1 publication(s) in Google Scholar
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.56%
- CAS 番号: 2169946-15-8
- 分子量:124.65kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Zanidatamab
More-
Cell Proliferation/Viability Assay
-
WB
EGFR アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
Isotype
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
HER2 |
体外実験
Zanidatamab (ZW25) has low nM binding affinity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells with a range of HER2 expression[1].
Zanidatamab inhibits the growth of human cancer cell lines with a wide range of HER2 expression (5-54% inhibition depending on the cell line), and inhibits ligand-mediated tumor cell proliferation[1].
Zanidatamab elicits concentration-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to 52% on TNBC cell lines expressing HER2 and exhibits synergy and additivity with multiple chemotherapeutic agents including platins, taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2 expressing tumor cell lines[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
遺伝子ID
アクセッション番号
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Loaded Zanidatamab on AHC2 biosensor, can bind HER2/CD340 Protein, Human (S310Y, HEK293, His, HY-P78680) with an affinity constant of 7.956E-11 M as determined in BLI assay. -
Immobilized Zanidatamab can bind Human Her2/ERBB2 Protein (ECD, His Tag). The EC50 for this effect is 3.09 ng/mL.
化学情報
-
CAS 番号 2169946-15-8
-
性状 Liquid
-
分子量 124.65kDa
-
Color Colorless to light yellow
-
SMILES
[Zanidatamab]
-
別名
ZW 25; ZW-49 Antibody
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
MAbs
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo. [Abstract]2024 Jan-Dec;16(1):2412881. PMID: 39381966
Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881. [Abstract]
Head-to-head comparison of KJ015, Zanidatamab (0.01-100 μg/mL, 120 h), and Anbenitamab in MDA-MB-175. All assays were repeated twice.
Zanidatamab purchased from MedChemExpress. Usage Cited in: MAbs. 2024 Jan-Dec;16(1):2412881. [Abstract]
Immunoblots of cell lysates from SK-Br-3 and NCI-N87 cells treated with IgG, Trastuzumab, Pertuzumab, tras+pert, or KJ015 at a final concentration of 50 nM for 24 h. Extra groups of anbenitamab and zanidatamab were added at the same concentration in MDA-MB-175 cells. Actin served as the loading control. T: trastuzumab, P: pertuzumab, T+P: tras+pert, Anbe: anbenitamab, Zani: zanidatamab.
純度とドキュメンテーション
-
データシート (259 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)